We use cookies for to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. View Our Policies Decline Accept News & Publications Careers Contact Us ABOUT NABRIVA PIPELINE & RESEARCH FOR INVESTORS Driven to Deliver Innovative Treatments for Patients With Infectious Diseases Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections. Learn More PIPELINE & RESEARCH Learn About Our Novel Antibiotic Candidates See Pipeline FOR INVESTORS Find Shareholder News, Events, & More Visit Investors Center CAREERS Join Our Growing Team at Nabriva View Jobs Collaborate With Us We’re developing innovative therapies that have the potential to transform the lives of people with infectious diseases, and our current platform is just the beginning. We actively seek collaborators and licensing opportunities focused on the discovery, development, and commercialization of technologies and therapies that address infectious diseases. Contact us to learn more. Contact Us Nabriva Response to COVID-19 Thank you to all the healthcare professionals for your tireless service on the frontlines of this pandemic. Due to COVID-19, the FDA has reported shortages of key drugs, including select antibiotics. Xenleta® (lefamulin) may be an alternative regimen for patients in need. Nabriva wants to reassure you that we have sufficient inventory of XENLETA IV and Oral tablets, available through designated specialty pharmacies or specialty distributors. Learn more at www.XENLETA.com. Again, to all the medical professionals, please be safe, take care of yourself and stay well. Best, Ted Schroeder CEO, Nabriva Therapeutics Continue to site In the News Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services 1 2 3 Prev Next Privacy Notice Patents Imprint Disclaimer Contact Us Careers Sitemap © Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland

Skip to main navigation News & Publications Careers Contact Us ABOUT NABRIVA PIPELINE & RESEARCH FOR INVESTORS SHARE PERFORMANCE Home / For Investors / Share Performance EVENTS & PRESENTATIONS PRESS RELEASES FINANCIAL PERFORMANCE SHARE PERFORMANCE SHAREHOLDER INFORMATION CORPORATE GOVERNANCE EMAIL ALERTS Stock Quote & Chart Stock Quote & Chart Historic Price Lookup Investment Calculator NASDAQ GS: NBRV $0.83 Nov 26, 2021 1:00 PM EST Change-0.0157 (-1.85%) Volume449,761 Today's Open$0.82 Previous Close$0.85 Today's High$0.84 Today's Low$0.82 52 Week High$4.58 52 Week Low$0.81 Data Provided by Refinitiv. Minimum 15 minutes delayed. Privacy Notice Imprint Disclaimer Contact Us Careers Sitemap © Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland